Phibro Animal Health (NASDAQ:PAHC) Rating Lowered to Hold at StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

A number of other brokerages also recently commented on PAHC. Morgan Stanley raised their target price on shares of Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Barclays raised their price objective on Phibro Animal Health from $20.00 to $22.00 and gave the company an “underweight” rating in a research report on Monday, February 10th. Two analysts have rated the stock with a sell rating and three have assigned a hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $21.00.

Phibro Animal Health Stock Up 0.6 %

Shares of NASDAQ PAHC opened at $21.64 on Tuesday. The stock has a market capitalization of $876.48 million, a PE ratio of 45.08, a P/E/G ratio of 0.45 and a beta of 0.58. The company has a quick ratio of 1.37, a current ratio of 3.20 and a debt-to-equity ratio of 2.99. The firm has a fifty day moving average of $22.75 and a 200-day moving average of $22.66. Phibro Animal Health has a 52-week low of $12.17 and a 52-week high of $26.55.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.14. Phibro Animal Health had a return on equity of 25.35% and a net margin of 1.75%. On average, analysts anticipate that Phibro Animal Health will post 1.95 EPS for the current year.

Hedge Funds Weigh In On Phibro Animal Health

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Phibro Animal Health by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 1,514,736 shares of the company’s stock worth $31,809,000 after acquiring an additional 20,604 shares during the last quarter. American Century Companies Inc. grew its stake in Phibro Animal Health by 18.0% during the 4th quarter. American Century Companies Inc. now owns 635,599 shares of the company’s stock valued at $13,348,000 after purchasing an additional 96,787 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in Phibro Animal Health by 21.4% during the 4th quarter. Nuveen Asset Management LLC now owns 588,001 shares of the company’s stock worth $12,348,000 after purchasing an additional 103,618 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Phibro Animal Health by 1.9% in the 4th quarter. Renaissance Technologies LLC now owns 557,800 shares of the company’s stock valued at $11,714,000 after purchasing an additional 10,600 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Phibro Animal Health by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 515,979 shares of the company’s stock valued at $10,838,000 after buying an additional 8,510 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.